Ark Biosciences of Shanghai Completes Series A Funding

Ark Biosciences, a Shanghai startup that is less than two years old, completed a Series A financing, led by Qiming Venture Partners and Morningside Ventures with participation by TF Capital. The size of the funding was not disclosed. Ark, which develops proprietary therapeutics for respiratory viral diseases and viral hepatitis, will use the money to fund clinical development of its leading RSV drug candidate, AK0529, along with several preclinical R&D programs targeting hepatitis B virus. AK0529 began a Phase I clinical trial in October 2014. More details.... Share this with colleagues: // //